Monograph Details
|
|
Endocrine System
> Pituitary disorders
|
|
Cabergoline |
| Manufacturer |
|
Various generic manufacturers |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Dopamine agonist. |
| Generic Name |
|
Cabergoline 0.5mg; scored tabs. |
| Indications |
|
Hyperprolactinemic disorders, either idiopathic or due to pituitary tumors. |
| Children |
|
Not recommended. |
| Adults |
|
Initially 0.25mg twice weekly. Dose may be increased at 4-week intervals by 0.25mg twice weekly. Max: 1mg twice weekly. |
| Contraindications |
|
Uncontrolled hypertension. Sensitivity to ergot alkaloids. |
| Precautions |
|
Not for pregnancy-induced hypertension or postpartum lactation inhibition or suppression. Respiratory or cardiac disease due to fibrosis. Hepatic dysfunction. Pregnancy (Cat.B). Nursing mothers: not recommended. |
| Interactions |
|
Concurrent dopamine D2 antagonists (eg, phenothiazines, butyrophenones, thioxanthines, metoclopramide): not recommended. Hypotension may be potentiated by antihypertensives. |
| Adverse Reactions |
|
GI upset, dizziness, fatigue, postural hypotension, nervousness, breast pain, dysmenorrhea, vision abnormalities; rare: fibrosis, valvulopathy. |
| How Supplied |
|
Contact supplier. |
|
|
|
|
